Manufacturers announces positive results for abrocitinib for moderate to severe atopic dermatitis in phase III trial

In the JADE COMPARE study, abrocitinib met its co-primary efficacy endpoints of superiority over placebo for skin clearance and severity of itch at week 12. These data, along with other results from the MONO-1 and MONO-2 trials will support filings with regulatory bodies.


Biospace Inc.